Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.

Juthani R, Madajewski B, Yoo B, Zhang L, Chen PM, Chen F, Turker MZ, Ma K, Overholtzer M, Longo VA, Carlin S, Aragon-Sanabria V, Huse JT, Gonen M, Zanzonico PB, Rudin CM, Wiesner U, Bradbury MS, Brennan CW.

Clin Cancer Res. 2019 Sep 12. pii: clincanres.1834.2019. doi: 10.1158/1078-0432.CCR-19-1834. [Epub ahead of print]

PMID:
31515460
2.

Spatial Distance Correlates With Genetic Distance in Diffuse Glioma.

Gates EDH, Yang J, Fukumura K, Lin JS, Weinberg JS, Prabhu SS, Long L, Fuentes D, Sulman EP, Huse JT, Schellingerhout D.

Front Oncol. 2019 Jul 30;9:676. doi: 10.3389/fonc.2019.00676. eCollection 2019.

3.

Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma.

Elshafeey N, Kotrotsou A, Hassan A, Elshafei N, Hassan I, Ahmed S, Abrol S, Agarwal A, El Salek K, Bergamaschi S, Acharya J, Moron FE, Law M, Fuller GN, Huse JT, Zinn PO, Colen RR.

Nat Commun. 2019 Jul 18;10(1):3170. doi: 10.1038/s41467-019-11007-0.

4.

Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.

Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II.

Ann Oncol. 2019 Sep 1;30(9):1521-1530. doi: 10.1093/annonc/mdz207.

PMID:
31282941
5.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN.

Neuro Oncol. 2019 Jul 4. pii: noz119. doi: 10.1093/neuonc/noz119. [Epub ahead of print]

PMID:
31276167
6.

Integrating germline and somatic genomic analysis to probe etiological mechanism in malignant glioma.

Ostrom Q, Bondy ML, Huse JT.

Oncotarget. 2019 May 3;10(33):3086-3087. doi: 10.18632/oncotarget.26897. eCollection 2019 May 3. No abstract available.

7.

Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases.

Ballester LY, Moghadamtousi SZ, Leeds NE, Huse JT, Fuller GN.

Acta Neuropathol Commun. 2019 Apr 29;7(1):63. doi: 10.1186/s40478-019-0721-7. No abstract available.

8.

Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.

Ostrom QT, Egan KM, Nabors LB, Gerke T, Thompson RC, Olson JJ, LaRocca R, Chowdhary S, Eckel-Passow JE, Armstrong G, Wiencke JK, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Amos CI, Huse JT, Barnholtz-Sloan JS, Bondy ML.

Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32318. [Epub ahead of print]

PMID:
30963577
9.

G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma.

Wang Y, Yang J, Wild AT, Wu WH, Shah R, Danussi C, Riggins GJ, Kannan K, Sulman EP, Chan TA, Huse JT.

Nat Commun. 2019 Feb 26;10(1):943. doi: 10.1038/s41467-019-08905-8.

10.

RBM10 truncation in astroblastoma in a patient with history of mandibular ameloblastoma: A case report.

Majd NK, Metrus NR, Santos-Pinheiro F, Trevino CR, Fuller GN, Huse JT, Chung C, Ketonen L, Anderson MD, Penas-Prado M.

Cancer Genet. 2019 Feb;231-232:41-45. doi: 10.1016/j.cancergen.2019.01.001. Epub 2019 Jan 9.

PMID:
30803556
11.

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA.

Cancer Discov. 2019 May;9(5):628-645. doi: 10.1158/2159-8290.CD-18-1489. Epub 2019 Feb 20.

PMID:
30787016
12.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

13.

Novel insights into the epigenetics of diffuse glioma.

Danussi C, Huse JT.

Mol Cell Oncol. 2018 Aug 24;5(5):e1472055. doi: 10.1080/23723556.2018.1472055. eCollection 2018.

14.

A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma.

Koehler JW, Miller AD, Miller CR, Porter B, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O'Sullivan MG, Rissi DR, Mark Simpson R, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK.

J Neuropathol Exp Neurol. 2018 Nov 1;77(11):1039-1054. doi: 10.1093/jnen/nly085.

15.

Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series.

Jacobs DI, Fukumura K, Bainbridge MN, Armstrong GN, Tsavachidis S, Gu X, Doddapaneni HV, Hu J, Jayaseelan JC, Muzny DM, Huse JT, Bondy ML.

Neuro Oncol. 2018 Nov 12;20(12):1625-1633. doi: 10.1093/neuonc/noy119.

PMID:
30165405
16.

Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease.

Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, Davies MA.

J Neuropathol Exp Neurol. 2018 Jul 1;77(7):628-635. doi: 10.1093/jnen/nly046.

17.

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.

Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger AB.

J Neuropathol Exp Neurol. 2018 Jun 1;77(6):437-442. doi: 10.1093/jnen/nly022.

18.

Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling.

Oldrini B, Curiel-García Á, Marques C, Matia V, Uluçkan Ö, Graña-Castro O, Torres-Ruiz R, Rodriguez-Perales S, Huse JT, Squatrito M.

Nat Commun. 2018 Apr 13;9(1):1466. doi: 10.1038/s41467-018-03731-w.

19.

Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.

Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB.

Oncoimmunology. 2018 Jan 16;7(4):e1412909. doi: 10.1080/2162402X.2017.1412909. eCollection 2018.

20.

FGFR1 tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia.

Ballester LY, Penas-Prado M, Leeds NE, Huse JT, Fuller GN.

Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2). pii: a002378. doi: 10.1101/mcs.a002378. Print 2018 Apr.

21.

Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.

Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT.

Nat Commun. 2018 Mar 13;9(1):1057. doi: 10.1038/s41467-018-03476-6.

22.

2016 World Health Organization Classification of Central Nervous System Tumors.

Wen PY, Huse JT.

Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1531-1547. doi: 10.1212/CON.0000000000000536. Review.

PMID:
29200109
23.

Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.

Turcan S, Makarov V, Taranda J, Wang Y, Fabius AWM, Wu W, Zheng Y, El-Amine N, Haddock S, Nanjangud G, LeKaye HC, Brennan C, Cross J, Huse JT, Kelleher NL, Osten P, Thompson CB, Chan TA.

Nat Genet. 2018 Jan;50(1):62-72. doi: 10.1038/s41588-017-0001-z. Epub 2017 Nov 27.

24.

EGFR and PDGFRA co-expression and heterodimerization in glioblastoma tumor sphere lines.

Chakravarty D, Pedraza AM, Cotari J, Liu AH, Punko D, Kokroo A, Huse JT, Altan-Bonnet G, Brennan CW.

Sci Rep. 2017 Aug 22;7(1):9043. doi: 10.1038/s41598-017-08940-9.

25.

Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas.

Yan D, Kowal J, Akkari L, Schuhmacher AJ, Huse JT, West BL, Joyce JA.

Oncogene. 2017 Oct 26;36(43):6049-6058. doi: 10.1038/onc.2017.261. Epub 2017 Jul 31.

26.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK.

Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.

27.

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.

Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, Trippett TM, Gilheeney SW, Khakoo Y, Lyden DC, De Braganca KC, Kolesar JM, Huse JT, Kramer K, Cheung NV, Dunkel IJ.

PLoS One. 2017 Jun 5;12(6):e0178593. doi: 10.1371/journal.pone.0178593. eCollection 2017.

28.

Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results.

Ballester LY, Huse JT, Tang G, Fuller GN.

Hum Pathol. 2017 Nov;69:15-22. doi: 10.1016/j.humpath.2017.05.005. Epub 2017 May 23.

PMID:
28549927
29.

ARID1B alterations identify aggressive tumors in neuroblastoma.

Lee SH, Kim JS, Zheng S, Huse JT, Bae JS, Lee JW, Yoo KH, Koo HH, Kyung S, Park WY, Sung KW.

Oncotarget. 2017 Jul 11;8(28):45943-45950. doi: 10.18632/oncotarget.17500.

30.

Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowitz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A.

Neuro Oncol. 2017 Oct 1;19(10):1380-1390. doi: 10.1093/neuonc/nox086.

31.

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB.

Neuro Oncol. 2017 Aug 1;19(8):1047-1057. doi: 10.1093/neuonc/nox026.

32.

A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors.

Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, Kolesar JM, Huse JT, Modak S, Wexler LH, Kramer K, Spasojevic I, Dunkel IJ.

Pediatr Blood Cancer. 2017 Jul;64(7). doi: 10.1002/pbc.26409. Epub 2016 Dec 30.

PMID:
28035748
33.

Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway.

Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, Saffery R, Sexton-Oates A, Blumcke I, Capper D, Karajannis MA, Benayed R, Chavez L, Thomas C, Serrano J, Borsu L, Ladanyi M, Rosenblum MK.

Acta Neuropathol. 2017 Mar;133(3):417-429. doi: 10.1007/s00401-016-1639-9. Epub 2016 Nov 3.

34.

Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood.

Huse JT.

Surg Pathol Clin. 2016 Sep;9(3):379-90. doi: 10.1016/j.path.2016.04.005. Review.

PMID:
27523967
35.

IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation.

Oktay Y, Ülgen E, Can Ö, Akyerli CB, Yüksel Ş, Erdemgil Y, Durası IM, Henegariu OI, Nanni EP, Selevsek N, Grossmann J, Erson-Omay EZ, Bai H, Gupta M, Lee W, Turcan Ş, Özpınar A, Huse JT, Sav MA, Flanagan A, Günel M, Sezerman OU, Yakıcıer MC, Pamir MN, Özduman K.

Sci Rep. 2016 Jun 10;6:27569. doi: 10.1038/srep27569.

36.

The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.

Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC, Joyce JA.

Science. 2016 May 20;352(6288):aad3018. doi: 10.1126/science.aad3018.

37.

Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations.

Roy DM, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J, Bose P, Lee W, Chan TA.

Cancer Cell. 2016 May 9;29(5):737-750. doi: 10.1016/j.ccell.2016.03.025.

38.

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB.

N Engl J Med. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10.

39.

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J.

N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.

40.

Radiotherapy and temozolomide for anaplastic astrocytic gliomas.

Nayak L, Panageas KS, Reiner AS, Huse JT, Pentsova E, Braunthal SG, Abrey LE, DeAngelis LM, Lassman AB.

J Neurooncol. 2015 May;123(1):129-34. doi: 10.1007/s11060-015-1771-8. Epub 2015 Apr 29.

41.

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY.

Clin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24.

42.

The Emerging Molecular Foundations of Pediatric Brain Tumors.

Huse JT, Rosenblum MK.

J Child Neurol. 2015 Nov;30(13):1838-50. doi: 10.1177/0883073815579709. Epub 2015 Apr 14. Review.

PMID:
25873586
43.

Survival in patients treated for anaplastic meningioma.

Moliterno J, Cope WP, Vartanian ED, Reiner AS, Kellen R, Ogilvie SQ, Huse JT, Gutin PH.

J Neurosurg. 2015 Jul;123(1):23-30. doi: 10.3171/2014.10.JNS14502. Epub 2015 Apr 10.

PMID:
25859807
44.

Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, Chan TA, Yamada Y, Beal K.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):368-75. doi: 10.1016/j.ijrobp.2015.01.004. Epub 2015 Mar 5.

45.

AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.

Hechtman JF, Sadowska J, Huse JT, Borsu L, Yaeger R, Shia J, Vakiani E, Ladanyi M, Arcila ME.

Mol Cancer Res. 2015 Jun;13(6):1003-8. doi: 10.1158/1541-7786.MCR-15-0062-T. Epub 2015 Feb 24.

46.

The evolving molecular genetics of low-grade glioma.

Venneti S, Huse JT.

Adv Anat Pathol. 2015 Mar;22(2):94-101. doi: 10.1097/PAP.0000000000000049. Review. Erratum in: Adv Anat Pathol. 2015 May;22(3):226.

47.

TERT promoter mutation designates biologically aggressive primary glioblastoma.

Huse JT.

Neuro Oncol. 2015 Jan;17(1):5-6. doi: 10.1093/neuonc/nou318. Epub 2014 Dec 1. No abstract available.

48.

The evolving role of molecular markers in the diagnosis and management of diffuse glioma.

Huse JT, Aldape KD.

Clin Cancer Res. 2014 Nov 15;20(22):5601-11. doi: 10.1158/1078-0432.CCR-14-0831. Review.

49.

Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"?

Huse JT, Diamond EL, Wang L, Rosenblum MK.

Acta Neuropathol. 2015 Jan;129(1):151-3. doi: 10.1007/s00401-014-1359-y. Epub 2014 Oct 31. No abstract available.

PMID:
25359109
50.

CMV and glioma--are we there yet?

Huse JT, Aldape K.

Neuro Oncol. 2014 Nov;16(11):1433-4. doi: 10.1093/neuonc/nou296. No abstract available.

Supplemental Content

Support Center